This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Achillion Pharmaceuticals, Inc.
Drug Names(s): ACH-1095
Description: ACH-1095 is a NS4A antagonist.
Deal Structure: In November 2004, Gilead and Achillion established an agreement granting Gilead worldwide rights for the research, development and commercialization of certain Achillion compounds for the treatment of hepatitis C.
In May 2009, Gilead indicated that it did not intend to initiate clinical development of ACH-1095. In September 2009, Achillion entered into an amendment to its license and collaboration agreement with Gilead so that Achillion may continue to develop ACH-1095 independently during an Interim Period, while Gilead may join the company in developing ACH-1095 at clinical proof-of-concept, as defined. Achillion will bear all costs associated with ACH-1095 development during the Interim Period. If Gilead elects to regain rights to ACH-1095, Gilead will reimburse Achillion for all ACH-1095 development costs incurred during the Interim Period, and all original milestone and royalty payments described in the License Agreement will again apply to ACH-1095. Gilead is under no...See full deal structure in Biomedtracker
Partners: Gilead Sciences, Inc.
Additional information available to subscribers only: